Anticancer drug resistance : advances in molecular and clinical research
Author(s)
Bibliographic Information
Anticancer drug resistance : advances in molecular and clinical research
(Cancer treatment and research, v. 73)
Kluwer Academic, 1994
Available at 8 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Note
Includes bibliographical references and index
Description and Table of Contents
Description
Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these failures and continues to be an area of active investigation.
Since the last volume in this series, we have learned that the energy-dependent drug efflux protein, p-glycoprotein, encoded by the MDR 1 gene, is a member of a family of structurally related transport polypeptides, thus allowing us to explore the relationship between structure and function. In addition to ongoing well designed clinical trials aimed at reversing MDR mediated drug resistance, the first gene therapy studies with the MDR 1 gene retrovirally transduced into human bone marrow cells are about to be initiated.
Although MDR is currently the most understood mechanism of drug resistance, we are uncovering increasing knowledge of alternative molecular and biochemical mechanisms of drug resistance to antimetabolites, cisplatin and alkylating agents and developing new strategies for circumventing such resistance.
It is clear that drug resistance is complex, and many mechanisms exist by which cancer cells may overcome the cytotoxicity of our known chemotherapeutic agents. As our understanding of each of these mechanisms expands, well designed models will be necessary to test laboratory hypotheses and determine their relationship to drug resistance in humans. It is this integration of basic science and clinical investigation that will both advance our scientific knowledge and result in the improvement of cancer therapy.
Table of Contents
- Preface. 1. Genetics of Drug Resistance
- J.L. Biedler, B.A. Spengler. 2. P-Glycoprotein Homologues
- E. Buschman, P. Lepage, P. Gros. 3. Role of Protein Kinase C in Multidrug Resistance
- C.A. O'Brian, N.E. Ward, K.R. Gravitt, D. Fan. 4. Transcriptional Regulation of Multidrug Resistance Gene Expression
- S.S. Thorgeirsson, T.W. Grant, J.A. Silverman. 5. In vitro Models of Multidrug Resistance
- L.M. Greenberger, D. Cohen, S.B. Horwitz. 6. In vivo Models of P-Glycoprotein-Mediated Multidrug Resistance
- M.M. Gottesman, G.H. Mickisch, I. Pastan. 7. Molecular Diagnosis of Multidrug Resistance
- C.E. Herzog, S.E. Bates. 8. Clinical Reversal of Multidrug Resistance
- B.I. Sikic, G.A. Fisher, B.L. Lum, N.A. Brophy, A.M. Yahanda, K.M. Adler, J. Halsey. 9. Role of Gene Amplification in Drug Resistance
- P.V. Schoenlein. 10. Biochemical Modulation as an Approach to Reversal of Antimetabolite Resistance
- P.J. O'Dwyer. 11. Mechanisms of Acquired Resistance to Cisplatin
- P.A. Andrews. 12. Mechanisms of Resistance to Alkylating Agents
- O.M. Colvin. 13. Mechanisms of Resistance to Topoisomerase Inhibitors
- A.Y. Chen, L.F. Liu. Index.
by "Nielsen BookData"